Summary of multivariate analysis between acute GVHD (II-IV) and clinical and genetic variables
| Variable . | n . | No. of events . | Hazard ratio . | 95% CI . | P . |
|---|---|---|---|---|---|
| In relation to recipient SNP combination | |||||
| Age, y | |||||
| 50 or younger | 210 | 73 | |||
| Older than 50 | 204 | 56 | .9 | .6-1.3 | .66 |
| Sex | |||||
| Male/male, female/female | 224 | 79 | |||
| Female/male | 100 | 27 | .6 | .4-1.0 | .07 |
| Male/female | 90 | 23 | .7 | .5-1.2 | .19 |
| Conditioning | |||||
| Myeloablative, fludarabine/ melphalan | 205 | 80 | 1.9 | 1.3-2.8 | .001 |
| RIC, fludarabine/ busulfan, fludarabine/treosulfan | 209 | 49 | |||
| Recipient SNP combination | |||||
| HR | 121 | 46 | 2.7 | 1.6-4.4 | < .001 |
| MR | 177 | 58 | 1.6 | 1.0-2.6 | .045 |
| LR | 116 | 25 | |||
| In relation to discrepancy effect | |||||
| Age, y | |||||
| 50 or younger | 185 | 64 | |||
| Older than 50 | 182 | 53 | 1.0 | .7-1.4 | .81 |
| Sex | |||||
| Male/male, female/female | 199 | 71 | |||
| Female/male | 88 | 24 | .7 | .4-1.1 | .14 |
| Male/female | 80 | 22 | .8 | .5-1.2 | .27 |
| Conditioning | |||||
| Myeloablative, fludarabine/ melphalan | 183 | 71 | 1.7 | 1.1-2.5 | .01 |
| RIC, fludarabine/ busulfan, fludarabine/treosulfan | 184 | 46 | |||
| Groups of discrepancy | |||||
| D1 | 63 | 28 | 3.9 | 2.2-6.7 | < .001 |
| D2 | 188 | 64 | 1.8 | 1.1-2.8 | .02 |
| D3 | 116 | 25 |
| Variable . | n . | No. of events . | Hazard ratio . | 95% CI . | P . |
|---|---|---|---|---|---|
| In relation to recipient SNP combination | |||||
| Age, y | |||||
| 50 or younger | 210 | 73 | |||
| Older than 50 | 204 | 56 | .9 | .6-1.3 | .66 |
| Sex | |||||
| Male/male, female/female | 224 | 79 | |||
| Female/male | 100 | 27 | .6 | .4-1.0 | .07 |
| Male/female | 90 | 23 | .7 | .5-1.2 | .19 |
| Conditioning | |||||
| Myeloablative, fludarabine/ melphalan | 205 | 80 | 1.9 | 1.3-2.8 | .001 |
| RIC, fludarabine/ busulfan, fludarabine/treosulfan | 209 | 49 | |||
| Recipient SNP combination | |||||
| HR | 121 | 46 | 2.7 | 1.6-4.4 | < .001 |
| MR | 177 | 58 | 1.6 | 1.0-2.6 | .045 |
| LR | 116 | 25 | |||
| In relation to discrepancy effect | |||||
| Age, y | |||||
| 50 or younger | 185 | 64 | |||
| Older than 50 | 182 | 53 | 1.0 | .7-1.4 | .81 |
| Sex | |||||
| Male/male, female/female | 199 | 71 | |||
| Female/male | 88 | 24 | .7 | .4-1.1 | .14 |
| Male/female | 80 | 22 | .8 | .5-1.2 | .27 |
| Conditioning | |||||
| Myeloablative, fludarabine/ melphalan | 183 | 71 | 1.7 | 1.1-2.5 | .01 |
| RIC, fludarabine/ busulfan, fludarabine/treosulfan | 184 | 46 | |||
| Groups of discrepancy | |||||
| D1 | 63 | 28 | 3.9 | 2.2-6.7 | < .001 |
| D2 | 188 | 64 | 1.8 | 1.1-2.8 | .02 |
| D3 | 116 | 25 |
Significant deviations (P < .05) are marked in bold.